|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenues | |||||
| Cost of Revenues | |||||
| Gross Profit | |||||
| Product Royalty Income | |||||
| Operating Expenses | |||||
| Salaries and wages | |||||
| Commissions and consulting expenses | |||||
| Professional fees | |||||
| Advertising and marketing | |||||
| Office lease and expenses | |||||
| Research and development costs | |||||
| Bad debt recovery | |||||
| General and administrative expenses | |||||
| Depreciation | |||||
| Impairment loss | |||||
| Total operating expenses | |||||
| Income (Loss) from Operations | |||||
| Other Income | |||||
| Interest and other income, net | |||||
| Total other Income | |||||
| Income (Loss) Before Provision for (Benefit from) Income Taxes | |||||
| Provision for (benefit from) Income taxes | |||||
| Net Income (Loss) Available to Common Shareholders | |||||
| Other comprehensive income (loss), net of $0 and ($49,800) deferred income taxes in 2025 and 2024 | |||||
| Foreign currency translation | |||||
| Total Comprehensive Income (Loss) | |||||
| Net Income (Loss) per Common Share | |||||
| Basic | |||||
| Diluted | |||||
| Weighted Average Number of Common Shares Outstanding | |||||
| Basic | |||||
| Diluted | |||||
Loading...
